APLLTD

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited (APLLTD) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

alembicpharmaceuticals.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹789.45
Market cap
15,526 Cr
Stock P/E
22.4
P/B
2.74
Dividend yield
1.4%
ROE (FY26)
11.8%
ROCE (FY26)
11.2%
Operating margin (FY26)
10.9%
Debt / equity (FY26)
0.24
OCF / EBITDA (FY26)
70.0%
OCF / EBITDA (3Y)
54.7%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Alembic Pharmaceuticals makes and sells medicines: branded formulations in India, generic formulations in the US and other international markets, and API, and it is building a branded specialty business in the US.

Company snapshot

35thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Debt-to-equity of 0.24x — the company is largely funded by its own money, not borrowed funds.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales1,595 Cr1,631 Cr1,517 Cr1,562 Cr1,648 Cr1,693 Cr1,770 Cr1,711 Cr1,910 Cr1,876 Cr1,848 Cr2,150 Cr
Operating expenses (approx.)1,387 Cr1,364 Cr1,257 Cr1,325 Cr1,409 Cr1,433 Cr1,498 Cr1,429 Cr1,594 Cr1,583 Cr1,620 Cr1,818 Cr
EBITDA208 Cr266 Cr260 Cr237 Cr239 Cr260 Cr272 Cr281 Cr316 Cr294 Cr228 Cr332 Cr
OPM %13.1%16.3%17.1%15.2%14.5%15.4%15.4%16.4%16.5%15.6%12.3%15.4%
Other income10 Cr3 Cr4 Cr2 Cr17 Cr10 Cr14 Cr7 Cr7 Cr16 Cr26 Cr15 Cr
Interest16 Cr15 Cr11 Cr13 Cr19 Cr22 Cr25 Cr24 Cr24 Cr23 Cr23 Cr28 Cr
Depreciation68 Cr69 Cr69 Cr69 Cr71 Cr70 Cr69 Cr74 Cr76 Cr80 Cr89 Cr98 Cr
Profit before tax135 Cr185 Cr183 Cr157 Cr180 Cr178 Cr192 Cr190 Cr224 Cr162 Cr119 Cr222 Cr
Tax %-1.4%2.2%2.5%14.3%15.1%22.5%18.4%19.2%17.9%18.3%-69.9%22.3%
Net profit137 Cr180 Cr178 Cr135 Cr153 Cr138 Cr157 Cr154 Cr184 Cr132 Cr202 Cr172 Cr
EPS (₹)₹6.95₹9.18₹9.07₹6.85₹7.79₹7.01₹7.98₹7.85₹9.40₹6.76₹10.31₹8.80

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3,135 Cr3,131 Cr3,935 Cr4,606 Cr5,393 Cr5,306 Cr5,653 Cr6,229 Cr6,672 Cr7,345 CrSign in free for the trailing twelve months
Operating expenses (approx.)2,519 Cr2,488 Cr3,061 Cr3,383 Cr3,836 Cr4,432 Cr4,944 Cr5,295 Cr5,664 Cr6,226 CrSign in free for the trailing twelve months
EBITDA615 Cr643 Cr874 Cr1,223 Cr1,558 Cr874 Cr708 Cr933 Cr1,008 Cr1,118 CrSign in free for the trailing twelve months
OPM %19.6%20.5%22.2%26.6%28.9%16.5%12.5%15.0%15.1%15.2%Sign in free for the trailing twelve months
Other income2 Cr7 Cr9 Cr5 Cr10 Cr50 Cr3 Cr28 Cr43 Cr54 CrSign in free for the trailing twelve months
Interest5 Cr3 Cr18 Cr27 Cr16 Cr18 Cr50 Cr56 Cr79 Cr94 CrSign in free for the trailing twelve months
Depreciation83 Cr105 Cr115 Cr157 Cr183 Cr287 Cr275 Cr273 Cr279 Cr319 CrSign in free for the trailing twelve months
Profit before tax525 Cr533 Cr740 Cr1,000 Cr1,400 Cr625 Cr355 Cr632 Cr707 Cr694 CrSign in free for the trailing twelve months
Tax %23.3%22.6%21.2%19.9%18.1%16.7%3.6%2.5%17.7%3.3%Sign in free for the trailing twelve months
Net profit403 Cr413 Cr583 Cr801 Cr1,147 Cr521 Cr342 Cr616 Cr582 Cr671 CrSign in free for the trailing twelve months
EPS (₹)₹21.39₹21.89₹31.00₹43.97₹60.81₹27.76₹17.40₹31.33₹29.68₹34.33Sign in free for the trailing twelve months
Dividend payout %————0.0%52.8%57.5%25.5%37.2%32.2%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital38 Cr38 Cr38 Cr38 Cr39 Cr39 Cr39 Cr39 Cr39 Cr39 Cr
Reserves1,865 Cr2,182 Cr2,681 Cr3,182 Cr5,088 Cr5,198 Cr4,331 Cr4,779 Cr5,152 Cr5,636 Cr
Borrowings89 Cr708 Cr928 Cr1,747 Cr200 Cr630 Cr636 Cr430 Cr1,196 Cr1,361 Cr
Other liabilities698 Cr1,013 Cr1,131 Cr1,051 Cr1,442 Cr1,255 Cr1,176 Cr1,197 Cr1,388 Cr1,733 Cr
Total liabilities2,689 Cr3,941 Cr4,778 Cr5,989 Cr6,709 Cr7,122 Cr6,183 Cr6,446 Cr7,773 Cr8,763 Cr
Fixed assets (net)799 Cr927 Cr1,098 Cr1,525 Cr1,704 Cr1,742 Cr2,398 Cr2,547 Cr2,524 Cr2,844 Cr
CWIP369 Cr911 Cr1,341 Cr1,574 Cr1,944 Cr2,206 Cr601 Cr524 Cr837 Cr634 Cr
Investments50 Cr42 Cr49 Cr18 Cr236 Cr118 Cr96 Cr93 Cr127 Cr141 Cr
Inventories633 Cr734 Cr967 Cr1,188 Cr1,486 Cr1,610 Cr1,475 Cr1,644 Cr2,288 Cr2,511 Cr
Trade receivables339 Cr526 Cr489 Cr865 Cr349 Cr807 Cr1,046 Cr1,025 Cr1,400 Cr1,466 Cr
Cash & bank153 Cr84 Cr199 Cr72 Cr98 Cr61 Cr75 Cr120 Cr83 Cr196 Cr
Other assets346 Cr718 Cr634 Cr748 Cr892 Cr578 Cr490 Cr493 Cr514 Cr971 Cr
Total assets2,689 Cr3,941 Cr4,778 Cr5,989 Cr6,709 Cr7,122 Cr6,183 Cr6,446 Cr7,773 Cr8,763 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity329 Cr312 Cr812 Cr449 Cr1,463 Cr552 Cr724 Cr803 Cr88 Cr783 Cr
Cash from investing-486 Cr-884 Cr-756 Cr-732 Cr-839 Cr-372 Cr-448 Cr-321 Cr-568 Cr-506 Cr
Cash from financing-129 Cr503 Cr59 Cr155 Cr-597 Cr-217 Cr-262 Cr-438 Cr444 Cr-164 Cr
Net cash flow-286 Cr-69 Cr115 Cr-128 Cr26 Cr-37 Cr14 Cr45 Cr-37 Cr113 Cr
Free cash flow (OCF − Capex)-182 Cr-509 Cr48 Cr-286 Cr804 Cr127 Cr281 Cr476 Cr-476 Cr288 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %26.6%18.3%20.8%20.8%26.9%11.0%8.1%13.1%12.3%11.2%
ROE %21.2%18.6%21.5%26.0%23.3%10.4%7.8%12.8%11.2%11.8%
Debtor days39614569245567607673
Inventory days327368414443456519430428498523
Days payable259381301233205228198191192174
Cash conversion cycle10848159278275347299296383422
OCF / EBITDA %53.4%48.6%92.9%36.7%94.0%63.2%102.2%86.1%8.7%70.0%
OCF / EBITDA % (3 years)——68.2%57.4%74.6%67.4%87.2%82.7%60.9%54.7%
Debt / equity0.050.320.340.550.040.120.150.090.230.24
Current ratio——1.311.412.011.621.782.121.691.75
Net debt / EBITDA-0.10—0.831.370.070.650.790.331.101.04